

## **IMMUNOTHERAPY BRIDGE**

**November 30<sup>th</sup> - December 1<sup>st</sup>, 2022**

### **SCIENTIFIC RATIONAL**

Over the last few years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies will be exhaustively discussed (lung, head and neck, ovarian, breast, gastrointestinal tract and lymphomas) and on targeting cancer through stimulation of innate immunity with intratumorals.

Then the "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.



## PRELIMINARY SCIENTIFIC PROGRAM

*\*\*Not included on CME accredited program*

### November 30<sup>th</sup>, 2022

10:40 10:45 Introduction and objectives, *Paolo A. Ascierto*

#### **SITC Session – CELL THERAPIES**

**Chairpersons:** *Lisa Butterfield, Marcela V. Maus*

10:45 11:00 TCR-T, TILs and CAR-T, *Raj Puri\**

11:00 11:15 Engineered NK cells for cancer immunotherapy, *Katy Rezvani*

11:15 11:30 CAR macrophages, *Matthias Stephan\**

11:30 11:45 Biomarkers and immune cell subsets, *Anne Monette\**

11:45 12:00 Best of SITC 2022 for clinical development and trials, *Paolo A. Ascierto*

12:00 12:30 Discussion LIVE

**12:30 13:00 LECTURE - TBD**

**13:00 14:00 Lunch\*\***

**14:00 14:55 SYMPOSIUM - TBD**

#### **Session 2 - Trends in immunotherapy**

**Chairpersons:** *John Haanen, Sandro Pignata\**

14:55 15:10 Head & Neck, *Robert Ferris\**

15:10 15:25 GU Cancer, *Akash Patnaik*

15:25 15:40 Colorectal Cancer, *Antonio Avallone*

15:40 15:55 GI Cancer, *Gregory B. Lesinski*

15:55 16:10 Breast cancer immunotherapy: moving forward, *Leisha Emens*

16:10 16:25 Ovarian Cancer, *Kunle Odunsi*

16:25 16:40 Trends in lymphoma immunotherapy and lessons for solid tumors, *Joshua Brody*

16:40 16:55 Non Melanoma Skin Cancers, *Paolo A. Ascierto*

16:55 17:25 Discussion LIVE

**17:25 17:40 Break\*\***



**3P Solution S.r.l.** a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

## GREAT DEBATE Session - DAY 1

**Chairpersons:** *Paolo A. Ascierto, Bernard A. Fox, Igor Puzanov*

- 17:40 18:10 Can computational biology approach improve clinical trial design? Yes or no  
*Samir N. Khleif VS TBD*
- 18:10 18:20 Discussion LIVE
- 18:20 18:50 Cell therapy for solid tumors: yes or no?  
*Renier Brentjens\* VS Kunle Odunsi*
- 18:50 19:00 Discussion LIVE

## December 1<sup>st</sup>, 2022

### Session 3 - Drivers of immune responses

**Chairpersons:** *Alfredo Budillon, Luigi Buonaguro*

- 09:15 09:30 Immunogenicity and therapeutic cross-protection to NRAS Q61 public neoantigens  
*Christopher Klebanoff*
- 09:30 09:45 Next generation cytokine therapy, *TBD*
- 09:45 10:00 New clinical data with novel immune checkpoints, *Tomas Kirchhoff*
- 10:00 10:15 Bispecific antibodies in cancer immunotherapy, *Omid Hamid*
- 10:15 10:30 *TBD, Chrystal Paulos*
- 10:30 10:45 Discussion LIVE
- 10:45 11:00 Targeting neutrophils to enhance antitumor immunity, *Brahm Segal*
- 11:00 11:15 Mechanisms of ICI toxicities across tumor types, *Ryan Sullivan*
- 11:15 11:30 Long-term toxicity and the impact on quality of life, *Douglas Johnson*
- 11:30 11:45 Evidence for adapting radiotherapy to immune checkpoint blockade, *Silvia Formenti*
- 11:45 12:00 *TBD, Carlo Bifulco*
- 12:00 12:15 Intracranial administration of immune checkpoint blockade in patients with recurrent glioblastoma, *Bart Neyns*
- 12:15 12:30 Discussion LIVE
- 12:30 13:20 SYMPOSIUM**  
*Non Melanoma Skin Cancer, Paolo A. Ascierto, Dirk Schadendorf\**
- 13:20 14:00 Lunch\*\***



**3P Solution S.r.l.** a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

## **GREAT DEBATE Session – DAY 2**

**Chairpersons:** *Paolo A. Ascierto, Bernard A. Fox, Igor Puzanov*

- 14:00 14:30 Periphery/blood biomarkers VS TME biomarkers  
*Ryan Sullivan VS Max Vicha\**
- 14:30 14:40 Discussion LIVE
- 14:40 15:10 CAR-T? Yes or No  
*Marco Ruella\* VS TBD*
- 15:10 15:20 Discussion LIVE

## **Session - NeoAdjuvant Immunotherapy**

**Chairpersons:** *Paolo A. Ascierto, Elizabeth Burton*

- 15:20 15:35 GU cancers, *Sangeeta Goswami\**
- 15:35 15:50 NSCLC, *Tina Cascone*
- 15:50 16:05 Breast Cancer, *Elizabeth Mittendorf\**
- 16:05 16:20 Non melanoma skin cancer, *Neil Gross*
- 16:20 16:35 Pathology perspectives, *Janis M. Taube*
- 16:35 16:50 Neoadjuvant trial design and clinical update in melanoma, *Alexander Menzies*
- 16:50 17:05 Personalization of neoadjuvant immunotherapy in melanoma, *Christian Blank*
- 17:05 17:35 Discussion LIVE
- 17:35 Conclusions, *Paolo A. Ascierto, Bernard A. Fox, Igor Puzanov*



**3P Solution S.r.l.** a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

## PRESIDENCY

**Paolo A. Ascierto** - Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

**Bernard A. Fox** - Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, US

**Patrick Hwu** - President & CEO, Moffitt Cancer Center, Tampa, FL, US

**Igor Puzanov** - Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics Buffalo, NY, US

## SCIENTIFIC BOARD

**Sanjiv S. Agarwala** - Professor & Chief, Haematology & Oncology, St Luke’s University Hospital and Temple University, Bethlehem, PA, US

**Paolo A. Ascierto** - Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

**Carlo Bifulco** - Medical Director, PSJH System Genomics Laboratory, Providence St. Joseph Health, Director and Member, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Lisa H. Butterfield** - Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, CA, US

**Elizabeth M. Burton** - Director, Melanoma Research Planning & Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Corrado Caracò** - Director of Melanoma and Skin Tumor Surgery, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

**Mary Dean** - Executive Director, Society of ImmunoTherapy for Cancer (SITC), Milwaukee, WI, US

**Sandra Demaria** - Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York City, NY, US



**Reinhard Dummer** - Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

**Bernard A. Fox** - Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, US

**Jerome Galon** - INSERM Laboratory of Integrative Cancer Immunology; Team labeled League Against Cancer; Cordeliers Research Center, Sorbonne University, University of Paris, Paris, France

**Claus Garbe** - Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen

**Omid Hamid** - Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, CA, US

**Patrick Hwu** - President & CEO, Moffitt Cancer Center, Tampa, FL, US

**Giuseppe Masucci** - M.D., Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

**Olivier Michielin** - Head of Precision Oncology Center and melanoma clinic, Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland

**Iman Osman** - Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, New York University Langone, Medical School, New York, NY, US

**Giuseppe Palmieri** - President, Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

**Michael A. Postow** - Memorial Sloan Kettering Cancer Center, New York, NY, US

**Igor Puzanov** - Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics Buffalo, NY, US

**Magdalena Thurin** - Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, US

**Tara Withington** - Executive Director Emeritus, Society of ImmunoTherapy for Cancer (SITC), Milwaukee, WI, US

